Jul 1 |
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
|
Jun 24 |
NeuroSense Therapeutics GAAP EPS of -$0.35 misses by $0.16
|
Jun 24 |
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
|
Jun 21 |
NeuroSense receives delisting notice from Nasdaq and intends to appeal
|
Jun 21 |
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
|
May 20 |
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
|
May 14 |
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
|
May 7 |
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
|
May 2 |
NeuroSense Announces First Quarter 2024 Business Update
|
Apr 22 |
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
|